Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06582966
PHASE4

Weekly Doxycycline DOT for STI Prevention Among Cisgender Women Taking HIV PrEP in Kisumu, Kenya

Sponsor: University of Washington

View on ClinicalTrials.gov

Summary

The first study of doxycycline postexposure prophylaxis for cisgender women did not reduce incident STIs likely due to low use of doxycycline. Researchers will conduct a pilot study of once-weekly doxyxycline to prevent bacterial STIs among Kenyan cisgender women using PrEP for HIV prevention.

Key Details

Gender

FEMALE

Age Range

18 Years - 30 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2024-08-13

Completion Date

2025-05-27

Last Updated

2026-04-13

Healthy Volunteers

No

Conditions

Interventions

DRUG

Doxycycline

Open label, single-arm, pilot study of 60 cisgender women taking HIV PrEP in Kisumu, Kenya will be given doxycycline 200 mg orally once weekly with clinical follow-up including quarterly STI testing and treatment for six months.

Locations (1)

Kenya Medical Research Institute -KEMRI

Kisumu, Kenya